Trial Profile
A phase I study of concomitant therapy with proteasome inhibitor PS-341 [bortezomib] and radiation in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 29 Sep 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 29 Sep 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 29 Sep 2011 Actual initiation date changed from Mar 2001 to Feb 2001 as reported by ClinicalTrials.gov.